# STANDING ORDER FOR NARCAN

Naloxone Hydrochloride/Narcan is indicated for the reversal of opioid overdose induced by natural or synthetic opioids in the setting of respiratory depression or unresponsiveness. It should not be given to anyone known to be hypersensitive to naloxone hydrochloride.

This standing order is current as of January 1, 2019.

Authority:

**North Dakota Century Code 23-01-42. Opioid antagonist prescription, distribution, possession, or use – Immunity from liability.**
2. A health care professional acting in good faith may directly or by standing order prescribe, distribute, or dispense an opioid antagonist, if the health care professional provides training to:
a. An individual at risk of experiencing an opioid-related overdose; or
b. A family member, friend, or other individual in a position to assist an individual at risk of experiencing an opioid-related overdose.

1. This standing order authorizes the MSU Campus Narcan Project to distribute nasal naloxone kits for the purposes of administering this medication to suspected overdose victims as part of a campus wide opioid overdose prevention effort.

2. This standing order authorizes MSU Campus Opioid Overdose First Responders to administer nasal naloxone to persons with suspected opioid overdose if they have successfully completed Opiod Overdose Prevention Training provided at Minot State University.

**NARCAN® (naloxone hydrochloride) nasal spray**
**Initial U.S. Approval: 1971**
**----------RECENT MAJOR CHANGES----------**
Dosage and Administration, Dosing in Adults and Pediatric Patients (2.2) 02/2017
**----------INDICATIONS AND USAGE----------**
NARCAN Nasal Spray is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression. (1)
NARCAN Nasal Spray is intended for immediate administration as emergency therapy in settings where opioids may be present. (1)
NARCAN Nasal Spray is not a substitute for emergency medical care. (1)
**----------DOSAGE AND ADMINISTRATION----------**
• NARCAN Nasal Spray is for intranasal use only. (2.1)
• Seek emergency medical care immediately after use. (2.1)
• Administration of a single spray of NARCAN Nasal Spray intranasally into one nostril. (2.2)
• Administer additional doses of NARCAN Nasal Spray, using a new nasal spray with each dose, if the patient does not respond or responds and then relapses into respiratory depression, additional doses of NARCAN Nasal Spray may be given every 2 to 3 minutes until emergency medical assistance arrives. (2.2)

• Additional supportive and/or resuscitative measures may be helpful while awaiting emergency medical assistance. (2.2)

**----------DOSAGE FORMS AND STRENGTHS----------**
Nasal spray: 2 mg and 4 mg of naloxone hydrochloride in 0.1 mL. (3)
**----------CONTRAINDICATIONS----------**
Hypersensitivity to naloxone hydrochloride. (4)
**----------WARNINGS AND PRECAUTIONS----------**
• Risk of Recurrent Respiratory and CNS Depression: Due to the duration of action of naloxone relative to the opioid, keep patient under continued surveillance and administer repeat doses of naloxone using a new nasal spray with each dose, as necessary, while awaiting emergency medical assistance. (5.1)
• Risk of Limited Efficacy with Partial Agonists or Mixed Agonists/Antagonists: Reversal of respiratory depression caused by partial agonists or mixed agonists/antagonists, such as buprenorphine and pentazocine, may be incomplete. Larger or repeat doses may be required. (5.2)
• Precipitation of Severe Opioid Withdrawal: Use in patients who are opioid dependent may precipitate opioid withdrawal. In neonates, opioid withdrawal may be life-threatening if not recognized and properly treated. Monitor for the development of opioid withdrawal. (5.3)
• Risk of Cardiovascular (CV) Effects: Abrupt postoperative reversal of opioid depression may result in adverse CV effects. These events have primarily occurred in patients who had pre-existing CV disorders or received other drugs that may have similar adverse CV effects. Monitor these patients closely in an appropriate healthcare setting after use of naloxone hydrochloride. (5.3)

**----------ADVERSE REACTIONS----------**
The following adverse reactions were observed in a NARCAN Nasal Spray clinical study: increased blood pressure, constipation, toothache, muscle spasms, musculoskeletal pain, headache, nasal dryness, nasal edema, nasal congestion, nasal inflammation, rhinalgia, and xeroderma. (6)

**Order to dispense:**
Upon participant completion of Overdose Prevention Training Program and documentation of competency, Nasal Naloxone may be dispensed and for use by a trained program participant:

**Nasal Naloxone Kits**:

1. Two doses: Naloxone Nasal (Narcan) 4mg/1mL
2. Step-by-step instructions for administration of nasal naloxone (Narcan)
3. Pocket Mask

**Directions for administration of nasal naloxone:** Administer nasal naloxone to a person suspected of an opioid overdose with respiratory depression or unresponsiveness as follows:

**KEY STEPS TO ADMINISTERING NARCAN® NASAL SPRAY:**

1. Peel back the package to remove the device. Hold the device with your thumb on the bottom of the plunger and two fingers on the nozzle.
2. Place and hold the tip of the nozzle in either nostril until your fingers touch the bottom of the patient's nose.

3. Press the plunger firmly to release the dose into the patient's nose.

**Not a Substitute for Emergency Medical Care.** When administering NARCAN® Nasal Spray, always be sure to call 911 right away, even if the person wakes up. Keep the patient under surveillance or close watch. If breathing does not return to normal or if breathing difficulty resumes, after 2-3 minutes, give an additional dose of NARCAN® Nasal Spray using a new device in the alternate nostril.

Do not administer nasal naloxone to a person with known hypersensitivity to naloxone.

X

Kelly Dickinson MSN, FNP
ND BON License #R35319